Hvidovre University Hospital
hvidovrehospital.dkLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
298
Active
22
Phase 3
16
Total enrollment
48,523
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Colesevelam | — | — | — | — | 3 | ||
| Semaglutide 2.4 mg, total diet replacement, behavioural intervention | — | — | — | — | — | 1 |
Next readouts
- 2026-10
- 2027-12
Top conditions
- Obesity15
- Postoperative Pain10
- Type 1 Diabetes10
- Type 2 Diabetes9
- Hip Fracture8
- Pain, Postoperative8
- Cirrhosis7
- Respiratory Failure6
Frequently asked questions about Hvidovre University Hospital
- How many clinical trials does Hvidovre University Hospital have on ClinicalTrials.gov?
- Hvidovre University Hospital is listed as the lead sponsor on 298 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hvidovre University Hospital's trials are in Phase 3?
- 16 of Hvidovre University Hospital's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Hvidovre University Hospital focus on?
- Hvidovre University Hospital's most-studied conditions on ClinicalTrials.gov are Obesity, Postoperative Pain, Type 1 Diabetes, Type 2 Diabetes, Hip Fracture.
- When are Hvidovre University Hospital's next clinical trial readouts?
- Hvidovre University Hospital has 2 upcoming primary-completion readouts tracked here; the soonest is “Semaglutide and Physical Activity for Obesity and Multimorbidity”, expected around 2026-10.